NOS2 and cancer: Another promising agent is bromodomain and extra-terminal (BET) inhibitor JQ1, which strongly suppresses cancer persistence and progression in vivo [51], and was recently shown to prevent iNOS transcription in ALA/light-challenged glioblastoma cells [51].